癌症支持治疗药物市场 - 增长、趋势、COVID-19 影响和预测(2022 - 2027 年)

癌症支持治疗药物市场按药物类别(G-CSF、ESAs、止吐药、双膦酸盐、阿片类药物、非甾体抗炎药和其他药物类别)和地理划分。

市场快照

Cancer Supportive Care Drugs Market Snapshot
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 3.56 %
Cancer Supportive Care Drugs Market Key Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

根据世界卫生组织 (WHO) 的数据,2018 年估计有 1810 万新癌症病例登记在案,2018 年还记录了约 960 万人死于癌症。此外,统计数据还报告了多年来癌症的患病率不断上升。这导致接受癌症治疗的患者人数增加。但是,癌症疗法与许多副作用有关。癌症支持治疗药物用于减轻癌症治疗的副作用。因此,癌症患病率的增加可能与该市场的增长直接相关。可支配收入的增加和医疗保健结构的改善也帮助人们获得癌症支持治疗药物,这也有助于这个市场的增长。

然而,靶向治疗药物的技术进步比传统癌症治疗药物的副作用更小,正在以更快的速度被采用。这直接影响了癌症支持药物市场的增长。其他因素,如癌症支持药物的副作用和严格的监管程序,也成为限制该市场的因素。

报告范围

癌症支持治疗药物用于通过保护某些细胞或器官来减轻癌症治疗的有害副作用。在报告中,提供了对癌症支持治疗药物市场的详细分析。市场按药物类别和地域划分。

By Drug Class
G-CSFs (Granulocyte colony-stimulating factor)
ESAs (Erythropoiesis stimulating agent)
Antiemetics
Bisphosphonates
Opioids
NSAIDs (Non Steroidal Anti-Inflammatory Drugs)
Topical
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

主要市场趋势

G-CSF 预计将在预测期内实现高增长

G-CSF 是一种生长因子,可帮助骨髓产生白细胞,以降低某些癌症治疗后感染的风险。G-CSF 还使干细胞从骨髓转移到血液中。干细胞是骨髓中负责产生红细胞、白细胞和血小板的细胞。

给予 G-CSF 以刺激骨髓产生干细胞并将其释放到血液中。然后在进行高剂量化疗之前收集干细胞。高剂量的化疗会阻止您的骨髓产生血细胞。因此,收集的干细胞用于干细胞移植以恢复骨髓的功能。

由于 G-CSF 有助于恢复对红细胞、白细胞和血小板的产生至关重要的骨髓功能,因此该药物类别正在被广泛采用。由于这些因素和癌症患病率的增加(根据疾病控制和预防中心,2018 年),预计该市场将在预测期内增长。

Cancer Supportive Care Drugs Market Trends

北美主导市场

北美是世界上癌症发病率最高的地区之一。根据美国国立卫生研究院的数据,2018 年美国的癌症患病率估计为每 100,000 人中有 439.2 人。根据加拿大癌症协会的数据,2017 年加拿大估计有 206,200 例新诊断的癌症和 80,800 例死于癌症。

尽管高患病率给该国人口带来负担,但美国和加拿大已经发展了医疗保健系统,因此在肿瘤学领域的治疗和研究上投入了大量资金。因此,这些国家吸引了大量的市场参与者。

Cancer Supportive Care Drugs Market Growth

竞争格局

大多数癌症支持治疗药物是由全球主要参与者生产的。拥有更多研究资金和更好分销系统的市场领导者已经在市场上确立了自己的地位。此外,亚太地区出现了一些小企业,这有助于这些地区的市场增长,也加剧了市场份额的竞争。

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Large Number of Side-effects Associated with Cancer Treatment

      2. 4.2.2 Rising Disposable Incomes and Constant Improvements in Healthcare Infrastructure

      3. 4.2.3 Increasing Prevalence of Cancer

    3. 4.3 Market Restraints

      1. 4.3.1 Advancements in Targated Therapy Drugs

      2. 4.3.2 Side Effects of Supportive Care Drugs

      3. 4.3.3 Stringent Regulatory Process

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Drug Class

      1. 5.1.1 G-CSFs (Granulocyte colony-stimulating factor)

      2. 5.1.2 ESAs (Erythropoiesis stimulating agent)

      3. 5.1.3 Antiemetics

      4. 5.1.4 Bisphosphonates

      5. 5.1.5 Opioids

      6. 5.1.6 NSAIDs (Non Steroidal Anti-Inflammatory Drugs)

      7. 5.1.7 Topical

      8. 5.1.8 Others

    2. 5.2 Geography

      1. 5.2.1 North America

        1. 5.2.1.1 United States

        2. 5.2.1.2 Canada

        3. 5.2.1.3 Mexico

      2. 5.2.2 Europe

        1. 5.2.2.1 Germany

        2. 5.2.2.2 United Kingdom

        3. 5.2.2.3 France

        4. 5.2.2.4 Italy

        5. 5.2.2.5 Spain

        6. 5.2.2.6 Rest of Europe

      3. 5.2.3 Asia-Pacific

        1. 5.2.3.1 China

        2. 5.2.3.2 Japan

        3. 5.2.3.3 India

        4. 5.2.3.4 Australia

        5. 5.2.3.5 South Korea

        6. 5.2.3.6 Rest of Asia-Pacific

      4. 5.2.4 Middle-East and Africa

        1. 5.2.4.1 GCC

        2. 5.2.4.2 South Africa

        3. 5.2.4.3 Rest of Middle-East and Africa

      5. 5.2.5 South America

        1. 5.2.5.1 Brazil

        2. 5.2.5.2 Argentina

        3. 5.2.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Amgen Inc.

      2. 6.1.2 Helsinn Healthcare

      3. 6.1.3 Heron Pharma

      4. 6.1.4 Johnson & Johnson

      5. 6.1.5 Merck & Co. Inc

      6. 6.1.6 Novartis (Sandoz)

      7. 6.1.7 F. Hoffmann-La Roche AG

      8. 6.1.8 Tesaro

      9. 6.1.9 Sanofi

      10. 6.1.10 Sun Pharmaceutical Industries Ltd.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Cancer Supportive Care Drugs Market market is studied from 2018 - 2026.

The Cancer Supportive Care Drugs Market is growing at a CAGR of 3.56% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Amgen Inc., Novartis AG, Merck & Co. Inc, F. Hoffmann-La Roche AG, Johnson & Johnson are the major companies operating in Cancer Supportive Care Drugs Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!